High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype

Archives of Neurology

Volumn 55, Issue 7, 1998, Pages 937-945

  Galasko, D ^a,b   Chang, L ^c   Motter, R ^d   Clark, C M ^e   Kaye, J ^f   Knopman, D ^g   Thomas, R ^a,b   Kholodenko, D ^d   Schenk, D ^d   Lieberburg, I ^d   Miller, B ^c   Green, R ^h   Basherad, R ⁱ   Kertiles, L ⁱ   Boss, M A ⁱ   Seubert, P ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b S Diego Vet Affairs Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Athena Neurosciences Inc   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^h GEORGIA STATE UNIVERSITY   (United States)

ⁱ ATHENA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; DNA; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDES; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 15644363081     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.7.937     Document Type: Article

References (52)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
2. Tierney MC, Fisher RH, Lewin AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurology. 1989; 38:359-369.
3. Morris JC, McKeel JW, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17-22.
4. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 1994;51:888-895.
5. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. Consortium to Establish a Registry for Alzheimer's Disease (CERAD), X. Neurology. 1995; 45:461-466.
6. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease: a clinicopathologic study. Arch Neural. 1996;53:35-42.
7. Mendez M, Mastri AR, Sung JH, Frey WH. Clinically diagnosed Alzheimer's disease: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord. 1992; 6:35-43.
8. Seubert P, Galasko D, Boss MA. Use of CSF-based markers in the diagnosis of Alzheimer's disease. In: Brioni J, Decker M, eds. Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations. New York, NY: Wiley-Liss Inc; 1997:345-366.
9. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbentassay. J Neurochem. 1993;61:1828-1834.
10. Vigo-Pelfry C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of Alzheimer's patients. Neurology. 1995; 45:788-793.
11. Motter R, Vigo-Pelfry C, Kholodenko D, et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995; 38:643-648.
12. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995;38:649-652.
13. Tato R, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1995;59:280-283.
14. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995;186:189-191.
15. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995;186:181-183.
16. Hock C, Golombowski S, Naser W, Muller-Spahn F. Increased levels of τ protein in cerebrospinal fluid of patients with Alzheimer's disease: correlation with degree of cognitive impairment. Ann Neurol. 1995;37:414-415.
17. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 1995;25:207-217.
18. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995;26:231-245.
19. Rosler N, Wichart I, Jellinger KA. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;60:237-238.
20. Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid by a newly developed sensitive Western blot assay. J Biol Chem. 1996;271:22908-22914.
21. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997;148: 41-45.
22. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
23. Weisgraber KH, Manley RW. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J. 1996;10:1485-1494.
24. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: highavidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
25. Strittmater WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol. 1994;125:163-171.
26. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
27. Hachinski V, Illif L, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
28. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
29. Brun A, Mann DMA, Englund L, et al. Consensus on clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994; 57:416-418.
30. McKeith IG, Galasko D, Kosaka K, et al. Consensus criteria for the clinical and pathological diagnosis of dementia with Lewy bodies: report of the CDLB International Workshop. Neurology. 1996;47:1113-1124.
31. Chui HC, Victoroff JI, Margolin DM, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473-480.
32. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol. 1976;6:278-296.
33. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1158-1159.
34. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning Using the RPART Routines. Rochester, Minn: Mayo Foundation; 1997.
35. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, Calif: Wadsworth International Group; 1984.
36. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E ∈4 allele with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
37. Saunders AM, Hulette C, Welsh-Bohmer KA, et al. Specificity, sensitivity, and predictive value of apolipoprotein E genotyping for sporadic Alzheimer's disease. Lancet. 1996;348:90-93.
38. Galasko D, Clark C, Chang L, et al. Cerebrospinal fluid levels of tau protein are increased early in the course of Alzheimer's disease. Neurology. 1997;48:632-635.
39. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosei Lett. 1996;212:209-211.
40. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649-9653.
41. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993; 11:575-580.
42. Johnson GVW, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem. 1997;68:430-433.
43. Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol. 1996;40:139-148.
44. Green J, Morris JC, Sandson J, McKeel DW, Miller JW. Progressive aphasia: a precursor of global dementia? Neurology. 1990;40:423-429.
45. Turner RS, Kenyon LC, Trojanowski JQ, Gonatas N, Grossman M. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann Neurol. 1996;39:166-173.
46. Gearing M, Olson DA, Watts RL, Mirra SS. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology. 1994;44:1015-1024.
47. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci. 1990;95:239-258.
48. Bancher C, Braak H, Fischer P, Jellinger K. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease. Neurosci Lett. 1993;162:179-182.
49. Whitehead AS, Bertrandy S, Finnan F, Butler A, Davey Smith G, Ben-Shiomo Y. Frequency of the apolipoprotein E ∈4 allele in a case-control study of early-onset Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;61:347-351.
50. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ∈4 in Alzheimer's disease. Ann Neurol. 1996;70:39-62.
51. Farrer LA, Abraham CR, Volicer L, et al. Allele ∈4 of apolipoprotein E shows a dose effect on age of onset of Pick's disease, Exp Neurol. 1995;136:162-170.
52. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele ∈4 is overrepresented in patients with the Lewy body varient of Alzheimer's disease. Neurology. 1994;44:1950-1951.